U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...
Sometimes, people with hypocalcemia will also go on to develop certain neurological or psychological symptoms, including depression, confusion, memory loss ... calcium absorption or increase its loss ...
A medicine that sidesteps the brain's dopamine receptors to reach different targets represents a new approach to ...